Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2009 Jun 1;284(30):20285–20298. doi: 10.1074/jbc.M109.004960

An Endoplasmic Reticulum Retention Signal Located in the Extracellular Amino-terminal Domain of the NR2A Subunit of N-Methyl-d-aspartate Receptors*

Shuang Qiu , Xiao-min Zhang , Jing-yuan Cao , Wei Yang , Ying-gang Yan , Ling Shan , Jie Zheng §, Jian-hong Luo ‡,1
PMCID: PMC2740454  PMID: 19487695

Abstract

N-Methyl-d-aspartate (NMDA) receptors play critical roles in complex brain functions as well as pathogenesis of neurodegenerative diseases. There are many NMDA isoforms and subunit types that, together with subtype-specific assembly, give rise to significant functional heterogeneity of NMDA receptors. Conventional NMDA receptors are obligatory heterotetramers composed of two glycine-binding NR1 subunits and two glutamate-binding NR2 subunits. When individually expressed in heterogeneous cells, most of the NR1 splice variants and the NR2 subunits remain in the endoplasmic reticulum (ER) and do not form homomeric channels. The mechanisms underlying NMDA receptor trafficking and functional expression remain uncertain. Using truncated and chimeric NMDA receptor subunits expressed in heterogeneous cells and hippocampal neurons, together with immunostaining, biochemical, and functional analyses, we found that the NR2A amino-terminal domain (ATD) contains an ER retention signal, which can be specifically masked by the NR1a ATD. Interestingly, no such signal was found in the ATD of the NR2B subunit. We further identified the A2 segment of the NR2A ATD to be the primary determinant of ER retention. These findings indicate that NR2A-containing NMDA receptors may undergo a different ER quality control process from NR2B-containing NMDA receptors.


Ionotropic glutamate receptors (iGluRs)2 mediate most of the excitatory neurotransmission in the central nervous system. They play key roles in complex brain functions as well as in the pathogenesis of neurodegenerative diseases. Based on pharmacological properties and sequence similarities, iGluRs can be grouped into three major subtypes: GluR1 to -4 subunits form α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, GluR5 to -7 and KA1 and -2 subunits make up kainate receptors, and NR1 together with NR2A to -D subunits comprise the NMDA receptors (1). All iGluR subunits share a unique membrane topology with a large extracellular NH2-terminal domain, three transmembrane segments (TM1 (transmembrane domain 1), TM3, and TM4), a P-loop region, and a cytoplasmic COOH terminus (2, 3). Based on the sequence homology to bacterial periplasmic binding proteins, the NH2-terminal domain of iGluRs can be divided into two domains in tandem: the amino-terminal domain (ATD), which includes the first 400 or so amino acids (4), and the following S1 domain preceding TM1, which forms the ligand-binding domain together with the extracellular loop between TM3 and TM4 (S2 domain) (5, 6).

Among iGluRs, NMDA receptors are special in that conventional NMDA receptors are obligatory tetrameric membrane proteins composed of two glycine-binding NR1 and two glutamate-binding NR2 subunits. The NR1 subunit is essential for the formation of functional NMDA receptor channel, whereas the NR2 subunit modifies channel properties, such as current kinetics and channel conductance (1). The major NR1 splice variant and the NR2 subunits are retained in the ER when expressed alone in heterogeneous cells. Only when expressed together do they form functional receptors on the cell surface (79). In the last decade, enormous progress has been made in understanding the phenomenology and mechanisms of functional plasticity of NMDA receptors. However, much less is known about the mechanisms underlying the ER retention of NMDA receptor subunits. Previous studies focused on the COOH terminus have shown that the NR1a subunit contains an ER retention signal, RRR, in the C1 cassette, whereas a motif, HLFY, found in the NR2B subunit immediately following the TM4 (10) or, at least, the presence of any two amino acid residues after NR2 TM4 (11) is required for the export of NR1-NR2 complexes from the ER. Recently, novel ER retention signals were identified in the TM3 of both NR1 and NR2B subunits. In addition, TM3 of both NR1 and NR2B and TM4 of NR1 are necessary for masking ER retention signals found in TM3 (12).

In the present study, we focused on the functional role of the ATD in the surface expression of NMDA receptors. Interestingly, we found an ER retention signal located in the ATD of the NR2A subunit but not in the corresponding domain of the NR2B. It is suggested that NR2A-containing NMDA receptors may undergo an ER quality control process different from that of NR2B-containing NMDA receptors.

EXPERIMENTAL PROCEDURES

Plasmid Construction

The expression vectors for XFP-NR1a, XFP-NR2A, XFP-NR2B, and GABAA α1-YFP have been described previously, in which XFP indicates CFP, YFP, or GFP (13, 14). The ATD-deleted, XFP-tagged NR1a, NR2A, or NR2B subunits used in this study were constructed from XFP-NR1a, XFP-NR2A, and XFP-NR2B, respectively, using conventional DNA mutagenesis techniques. In this report, NR1aΔATD means that the first 390-amino acid residues of the NR1a subunit were deleted, NR2AΔATD means that the first 391 amino acid residues of the NR2A subunit were deleted, and NR2BΔATD means that the first 392 amino acid residues of the NR2B subunit were deleted (Fig. 1A). NR2AATD-2B and NR2BATD-2A represent chimeras in which the ATD of the first subunit was substituted with the ATD of the second subunit (Fig. 4A). For example, NR2AATD-2B means that the ATD of the NR2A subunit was substituted with that of the NR2B subunit. NR2AΔATD-A1, NR2AΔATD-A2, or NR2AΔATD-A3 were constructed by inserting an NR2A A1, A2, or A3 segment into the SacII site of NR2AΔATD, whereas NR2AΔATD-A2-2B was constructed by inserting the NR2B A2 segment into the SacII site of NR2AΔATD, as illustrated in Fig. 8A. pDisplay-GFP was constructed by fusing GFP with the pDisplay vector between the XmaI and SacII sites by PCR amplification. The chimeras between the ATD of the NR1a, NR2A, or NR2B subunit and pDisplay-GFP were made by fusing the ATD of these subunits into the pDisplay-GFP at the SalI site and were named GFP-ATD1a, GFP-ATD2A, or GFP-ATD2B, respectively (Fig. 5A). ATD1a or ATDGluR2 was constructed by fusing the ATD of the NR1a subunit or the GluR2 subunit into the pDisplay at the SalI or SacII site (see Fig. 5A and supplemental Fig. 4A). GFP-A22A or GFP-A22B was constructed by fusing the A2 segment of the NR2A subunit or NR2B subunit into the pDisplay-GFP at the SacII site, respectively (Fig. 8C). NR2BA2-2A means the A2 segment of the full-length NR2B subunit was substituted with that of the NR2A subunit (Fig. 8A), and GFP-ATD2B-A2-2A means the A2 segment of the GFP-ATD2B was substituted with that of the NR2A subunit (Fig. 8C), which was subcloned by using an In-FusionTM 2.0 Dry-Down PCR cloning kit (Clontech). According to the results from amino acid sequence alignment of the A2 segment of the NR2A and NR2B subunits, we selected 10 residues in the NR2A A2 segment with highly diverse side chain chemical natures (Fig. 8E). Each of them was replaced with the corresponding residue in the NR2B A2 segment. For example, I176Y means the isoleucine at position 176 of the NR2A A2 segment was replaced with a tyrosine (corresponding to Tyr175 in the NR2B A2 segment). All site-directed mutagenesis manipulation was done using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA). GFP-A22A-a, GFP-A22A-b, and GFP-A22A-c were constructed by fusing part of a (Ile151–Asp192), b (Asn193–Leu238), or c (Ile239–Asp282) of the NR2A A2 segment into the pDisplay-GFP at the SacII site, respectively (Fig. 8F). For each construct, the amino acid number (relative to the first methionine in the open reading frame) at the appropriate junction is indicated in Figs. 1A, 4A, and 8, A and F. All constructs were verified with DNA sequencing.

FIGURE 1.

FIGURE 1.

ATD of NR1a or NR2B subunit is not required for the formation of functional NR1a/NR2B receptors. A, schematic diagram of the NR subunit deletion constructs. ATD represents the first ∼400 amino acids, and XFP (dotted box) represents the fluorescent protein CFP or YFP. The hatched box corresponds to the signal peptide, the dotted line corresponds to the deleted ATD region, and the black boxes correspond to TM. The number above each NR subunit deletion construct indicates the residues deleted. B, HEK 293 cells expressing the indicated cDNAs were surface-stained with anti-GFP antibodies. CFP was tagged to the NR1a or ATD-deleted NR1a subunit, whereas YFP was tagged to the NR2B or ATD-deleted NR2B subunit (two left columns). The right column was from surface staining using anti-GFP antibody and Cy3-conjugated secondary antibody. Scale bar, 10 μm. C, the percentages of cells with detectable surface labeling were determined for >200 YFP-expressing cells for each combination of cDNAs in three experiments. The gray boxes represent YFP. The bar graphs represent mean ± S.E. **, p < 0.01, ANOVA. D, data represent mean ± S.E. of fluorescence intensities per unit area obtained for surface (black) or total YFP (white) expression. More than 60 YFP-expressing cells for each combination of cDNAs were analyzed in three experiments. E, representative glutamate-evoked currents recorded from HEK 293 cells. Glutamate (100 μm) and glycine (10 μm) were added to evoke currents. F, summary data showing the average peak amplitudes of the whole-cell currents when co-expressing NR1a or ATD-deleted NR1a and NR2B or ATD-deleted NR2B. The numbers above the histogram bars indicate the number of cells responding of the total number of recorded cells (i.e. 6/6 represents six responsive cells of six).

FIGURE 4.

FIGURE 4.

Surface expression and functional analysis of NMDA receptors containing NR2 chimeras with ATDs exchanged between NR2A and NR2B subunits. A, schematic diagram of the NR2 chimeric constructs. Gray bar, NR2A subunit; white bar, NR2B subunit. Hatched boxes, signal peptide; black boxes, transmembrane domain. B, HEK 293 cells co-expressing indicated cDNAs were immunostained for surface XFP. Scale bar, 10 μm. C, summary data showing percentages of HEK 293 cells with detectable surface labeling. **, p < 0.01, unpaired t test. D, summary data showing the average peak amplitude (pA) of the whole-cell currents when co-expressing NR1a or ATD-deleted NR1a subunits and NR2AATD-2B or NR2BATD-2A subunits.

FIGURE 8.

FIGURE 8.

A2 segment of NR2A ATD contains an ER retention signal. A, schematic diagram of the NR2AΔATD-A1,A2,A3, NR2AΔATD-A2-2B, and NR2BA2-2A. Gray bar, NR2A subunit; white bar, NR2B subunit; hatched box, signal peptide. The numbers above the NR2A or NR2B subunits indicate the residues deleted. B, the percentages of cells with detectable surface labeling were determined for >200 GFP-expressing cells for each combination of indicated cDNAs in three experiments. The bar graphs represent mean ± S.E. **, p < 0.01, unpaired t test. C, schematic diagram of chimeras between A2 segments of NR2A or NR2B subunits and pDisplay-GFP. Dotted box, GFP. D, the percentages of cells with detectable surface labeling were determined for >200 GFP-expressing cells for each indicated cDNA in three experiments. The bar graphs represent mean ± S.E. **, p < 0.01, ANOVA. E, the amino acid sequence alignment of the A2 segment of the NR2A and NR2B subunits. Triangles, sites at which mutations were introduced to the A2 segment. F, the A2 segment of NR2A ATD was further split into three parts named A22A-a, A22A-b, and A22A-c. This panel shows the chimeras of these sections with pDisplay-GFP. G, the percentages of cells with surface staining were determined for >200 GFP-expressing cells for each indicated cDNA in three experiments. The bar graphs represent mean ± S.E. H, surface (black) and total GFP (white) expressions. More than 60 GFP-expressing cells for each indicated cDNA were analyzed in three experiments.

FIGURE 5.

FIGURE 5.

NR2A ATD possesses an ER retention signal, and NR1a ATD is necessary for overcoming this signal. A, diagram of chimeric constructs between ATD and pDisplay-GFP. Dotted box, fluorescent protein GFP. Hatched box, signal peptide; black box, transmembrane domains of platelet-derived growth factor receptor. B, HEK 293 cells transfected with indicated cDNAs were surface-stained with anti-GFP antibodies. Scale bar, 20 μm. C, the percentages of cells with detectable surface labeling were determined for >200 GFP-expressing cells for each indicated cDNA in three experiments. The bar graphs represent mean ± S.E. **, p < 0.01, ANOVA. D, surface (black) and total GFP (white) expression. More than 60 GFP-expressing cells for each indicated cDNA were analyzed in three experiments. **, p < 0.01, ANOVA.

Cell Culture and Transfection

HEK 293 cells and COS-7 cells were grown in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum and antibiotics (all from Invitrogen), and transfected with appropriate plasmids (3–4 μg/35-mm dish, 6–8 μg/60-mm dish) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The transfection mixture was replaced 3–5 h after transfection with fresh culture medium. Ketamine (0.5 mm; Sigma) and kynurenic acid (1 mm; Sigma) were added to the media to protect the cells from NMDA receptor-mediated toxicity. Cells were examined within 2 days after transfection in an extracellular solution composed of 145 mm NaCl, 5 mm KCl, 2 mm CaCl2, 5 mm glucose, 0.01 mm glycine, and 5 mm HEPES at pH 7.4 with NaOH. Hippocampal neuronal cultures were prepared according to the protocol described previously (13). At 5 days in vitro, appropriate plasmids (3–4 μg/35-mm dish) were added with 4 μl of Lipofectamine 2000. After a 3-h incubation at 37 °C, cells were washed twice with serum-free medium, and the serum-containing culture medium was added. Expression of exogenous DNA was typically detected in 7 days in vitro neurons.

Surface Immunostaining and Quantitative Analysis

The methods used for surface immunostaining and quantitative analysis have been described previously (11, 13). Briefly, the transfected HEK 293 cells or hippocampal neurons were incubated with rabbit anti-GFP antibody (Chemicon) for 7 min, rinsed three times in extracellular solution, and then incubated with Cy3-conjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch Laboratories) for another 7 min. After another brief wash in extracellular solution, cells were immediately fixed and examined through a 60×, 1.4 numerical aperture oil immersion objective on a TE 2000 inverted microscope (Nikon, Tokyo, Japan) equipped with Metamorph version 5.0 software (Universal Imaging, West Chester, PA). All procedures were performed at room temperature. Surface expression of XFP-tagged NMDA receptor (NR) subunits in HEK 293 cells or hippocampal neurons was measured as the percentage of surface-stained cells (red) in the population of total cells transfected with XFP fusion proteins (green). For each sample, more than 200 XFP-positive HEK 293 cells or 50 XFP-positive hippocampal neurons were counted, and the means were obtained from three different cultures. The average intensities of surface (Cy3) and total fluorescence (GFP) were determined for regions outlined around the transfected HEK 293 cells or for regions outlined around the cell body of transfected hippocampal neurons. The optical signal level from nontransfected cells was considered as background. Intensity measurements are expressed in arbitrary units per unit area. For each sample, more than 60 XFP-positive HEK 293 cells or 30 XFP-positive neurons were counted, and the means were obtained from three different cultures. All data are presented as the mean ± S.E. Differences were tested using Student's t test or a one-way ANOVA test followed by the Newman-Keuls multiple comparison test.

Electrophysiology

The electrophysiological methods have been described previously (11). The extracellular recording solution contained 145 mm NaCl, 3 mm KCl, 10 mm HEPES, 3 mm CaCl2, 8 mm glucose, 2 mm MgCl2 (310 mosmol, pH adjusted to 7.30 with NaOH). Patch pipettes were filled with an intracellular solution containing 136.5 mm potassium gluconate, 17.5 mm KCl, 9 mm NaCl, 1 mm MgCl2, 10 mm HEPES, 0.2 mm EGTA (310 mosmol, pH adjusted to 7.20 with KOH). Recordings were made at −60 mV during the application of 100 μm glutamate and 10 μm glycine or 50 μm D-AP5, an antagonist of NMDA receptors.

Immunocytochemistry

Cultured COS-7 cells were fixed in 4% paraformaldehyde in PBS for 10 min and permeabilized in PBS containing 0.4% Triton X-100 and 5% bovine serum albumin for 30 min at room temperature. Cells were then incubated in primary mouse monoclonal PDI antibody (a marker for ER; Abcam), 58K antibody (a marker for Golgi; Abcam), 19 S S5A antibody (a marker for proteosome; Abcam), EEA1 antibody (a marker for early endosome; BD Biosciences), LAMP2 antibody (a marker for lysosome; Abcam), or NR1a (BD Biosciences) antibody, with or without primary rabbit polyclonal GFP antibody, in PBS containing 5% bovine serum albumin for 1 h. After washing three times with PBS, cells were incubated in anti-mouse Alexa-594-conjugated secondary antibody (Molecular Probes, Inc., Eugene, OR), with or without anti-rabbit Alexa-488-conjugated secondary antibody (Molecular Probes), in PBS containing 5% bovine serum albumin for another 1 h. After washing three times with PBS, cells were observed on a Fluoview FV1000 confocal microscope (Olympus). The primary antibody was used at 1:200 for PDI, 58K, LAMP2, EEA1, and GFP antibody and 1:100 for NR1a and 19 S S5A antibody, whereas the secondary antibody was used at 1:2000.

Detection of FRET Using Three-cube FRET Measurement

The fluorescence imaging work station for FRET and the FRET quantification method have been described previously (14). Briefly, the fluorescence imaging workstation consisted of a TE2000 inverted microscope (Nikon, Tokyo, Japan) equipped with a halogen lamp light source (100 watts), Dual-ViewTM (Optical Insights, LLC, Santa Fe, NM), and a SNAP-HQ cooled CCD camera (Roper Scientific, Trenton, NJ). MetaMorph version 5.0 software (Universal Imaging, West Chester, PA) was used to control the CCD camera and for analysis of the cell image data. Three-cube FRET filter cubes were as follows (excitation; dichroic; emission; company): YFP (S500/20 nm; Q515lp; S535/30 nm; Chroma); FRET (S430/25 nm; 455dclp; S535/30 nm; Chroma); and CFP (S430/25 nm; 455dclp; S470/30 nm; Chroma). Binning 2 × 2 modes and a 200-ms integration time were used. Average background signal was determined as the mean fluorescence intensity from a blank area and was subtracted from the raw images before carrying out FRET calculations. The FRET ratio (FR) was calculated with Equation 1 (1416).

graphic file with name zbc03009-8346-m01.jpg

SCUBE(SPECIMEN) denotes an intensity measurement, where CUBE indicates the filter cube (CFP, YFP, or FRET), and SPECIMEN indicates whether the cell is expressing donor (D; CFP), acceptor (A; YFP), or both (DA). RD1 = SFRET(D)/SCFP(D), and RA1 = SFRET(A)/SYFP(A).

Crude Membrane Preparation and Deglycosylation Analysis

To prepare a crude membrane suspension, the transfected HEK 293 cells were suspended and homogenized in lysis buffer (phosphate buffer, pH 7.4, containing 20 mm EDTA, 1 mm AEBSF, 50 μg/ml leupeptin, and 10 μg/ml aprotinin). Samples were then centrifuged (30,000 × g for 30 min at 4 °C), and cell membranes were resuspended in 50 μl of lysis buffer plus 1% SDS and 5% β-mercaptoethanol and boiled for 5 min before adding 1% Nonidet P-40 plus protease inhibitors as above. Samples were then partitioned into thirds; samples were treated with 0.4 units of N-glycosidase F (Roche Applied Science), 0.006 units of endoglycosidase H (Roche Applied Science), or control saline and incubated overnight. Reactions were terminated with 4× SDS-PAGE sample buffer and boiling for 5 min. Membrane proteins were resolved on a 6% SDS-polyacrylamide gel and visualized using immunoblot analysis with anti-GFP antibody.

RESULTS

Neither the NR1a ATD nor the NR2B ATD Is Required for the Formation and Surface Expression of NR1a/NR2B Receptors

In order to determine the role of the ATD in the trafficking of NMDA receptors, we generated a series of ATD deletions in fluorescent protein-tagged NR1a, NR2B, and NR2A subunits (Fig. 1A). We first used surface immunostaining to determine whether ATD deletion affected the trafficking of NR1a/NR2B-containing NMDA receptors to the cell membrane. Because the fluorescent protein was tagged to the extracellular side of each subunit, the expression of NR1a or NR2B in the plasma membrane could be detected in live cells by immunostaining of the fluorescent proteins. We used a polyclonal anti-GFP antibody followed by a Cy3-conjugated secondary antibody to label the receptors; expression in the plasma membrane was indicated by the presence of red puncta scattered on the cell surface. When we co-expressed CFP-NR1aΔATD and YFP-NR2B, CFP-NR1a and YFP-NR2BΔATD, or CFP-NR1aΔATD and YFP-NR2BΔATD, we detected clearly positive surface staining (Fig. 1B). To further quantitatively analyze the ability of NMDA receptors containing ATD-deleted NR subunits to traffic to the plasma membrane, we measured the percentage of cells with positive immunolabeling over the number of transfected cells indicated by the presence of YFP fluorescence. The results showed that when NR1a was co-expressed with YFP-NR2B, 77.6 ± 1.8% of cells had positive surface labeling. Similarly, when HEK 293 cells were co-transfected with NR1aΔATD and YFP-NR2B, NR1a and YFP-NR2BΔATD, or NR1aΔATD and YFP-NR2BΔATD, the percentage of cells with positive surface labeling decreased compared with NR1a/YFP-NR2B but was still high (57.8 ± 5.5, 51.6 ± 5.0, and 55.8 ± 6.9%, respectively) (Fig. 1C). Subsequent intensity analysis revealed no significant differences in the fluorescence intensities of the surface labeling or total YFP among NR1a/YFP-NR2B, NR1aΔATD/YFP-NR2B, NR1a/YFP-NR2BΔATD, and NR1aΔATD/YFP-NR2BΔATD (Fig. 1D). These data indicate that the ATD of NR1a or NR2B subunits was not required for the successful delivery of NR1a/NR2B receptors to the cell surface, although the ability of these receptors to be trafficked to the cell membrane was reduced to some degree. We further investigated the expression and trafficking of NR1a or NR2B subunits with the ATD deleted in cultured hippocampal neurons (supplemental Fig. 1). These experiments showed that YFP-NR1aΔATD or YFP-NR2BΔATD expressed alone in hippocampal neurons was able to express in the cell membrane, probably by co-assembly with endogenous NR2 or NR1 subunits.

To determine whether the surface-expressed complexes were functional, we recorded NMDA receptor currents in response to local application of saturating doses of glutamate (100 μm) and glycine (10 μm) in HEK 293 cells. Representative current traces through these deletion mutants evoked by a 500-ms glutamate application are shown in Fig. 1E, and the mean peak current amplitudes are shown in Fig. 1F. In close agreement with the live cell surface immunostaining results, currents were obtained from cells transfected with NR1a/YFP-NR2B, NR1aΔATD/YFP-NR2B, NR1a/YFP-NR2BΔATD, and NR1aΔATD/YFP-NR2BΔATD; the average amplitudes of the glutamate-evoked currents in picoamperes were 326.86 ± 69.20 (n = 6), 149.36 ± 19.24 (n = 7), 114.54 ± 15.55 (n = 7), and 172.84 ± 22.34 (n = 7), respectively. These data strongly suggested that deletion of the whole ATD did not eliminate the formation of functional channels between NR1a and NR2B subunits.

Surface Expression of NMDA Receptors Composed of ATD-deleted NR1a and Full-length NR2A Was Abolished

When HEK 293 cells co-expressing CFP-NR1aΔATD and the full-length YFP-NR2A subunit were analyzed for cell surface expression by immunoassay, no positive staining was detectable (Fig. 2A). This was true even for cells exhibiting clear intracellular CFP or YFP fluorescence signals, indicating strong expression of NR subunit proteins. This result is consistent with previous findings that the mutant NR1a subunit missing ATD cannot form receptors with the NR2A subunit in the plasma membrane (17). However, when CFP-NR1a subunits were co-expressed with YFP-NR2AΔATD subunits or when CFP-NR1aΔATD subunits were co-expressed with YFP-NR2AΔATD subunits, we found positive surface staining (Fig. 2A). In addition, significant surface staining was also observed when YFP-NR2AΔATD was expressed in hippocampal neurons (supplemental Fig. 1), which indicated that ATD-deleted NR2A subunits were able to co-assemble with endogenous NR1 subunits and express in the surface membrane. We also measured the percentage of transfected cells with positive surface staining. When HEK 293 cells were co-transfected with NR1a/YFP-NR2A, 66.0 ± 3.6% of cells had positive surface labeling. When NR1a/YFP-NR2AΔATD or NR1aΔATD/YFP-NR2AΔATD was co-transfected, the corresponding percentages were 46.0 ± 4.2 and 60.1 ± 1.2%, respectively (Fig. 2B). However, when NR1aΔATD/YFP-NR2A was co-transfected, the corresponding percentage was 2.4 ± 0.7%, which was significantly lower than that for NR1a/YFP-NR2A (Fig. 2B) and was not statistically different from the percentage when YFP-NR2A was expressed alone (2.9 ± 1.4%). The total intensity of YFP fluorescence showed no significant difference among NR2A or ATD-deleted NR2A, whereas the fluorescence intensity of the surface staining of NR1aΔATD/YFP-NR2A was significantly different from that of NR1a/YFP-NR2A (Fig. 2C). These results thus showed that NR1aΔATD/YFP-NR2A co-expression did not yield any surface protein, whereas the other combinations did. In agreement with the live cell surface immunostaining, no current response was detected from cells transfected with NR1aΔATD/YFP-NR2A (Fig. 2, D and E). In contrast, significant currents were recorded in cells expressing NR1a/YFP-NR2A, NR1a/YFP-NR2AΔATD, or NR1aΔATD/YFP-NR2AΔATD; the average amplitudes of glutamate-evoked currents in picoamperes were 147.12 ± 13.17 (n = 4), 107.15 ± 25.90 (n = 4), and 139.10 ± 31.11 (n = 6), respectively (Fig. 2, D and E). Taken together, these results indicated that NR1a/NR2A receptors with NR2A ATD deleted were still delivered to the surface membrane, whereas NR1a/NR2A receptors with NR1a ATD deleted could not be delivered to the surface membrane.

FIGURE 2.

FIGURE 2.

NR1aΔATD/NR2A receptor complexes are not delivered to surface membrane. A, HEK 293 cells co-expressing indicated cDNAs were surface-stained with anti-GFP antibodies. CFP was tagged to the NR1a or ATD-deleted NR1a subunit, whereas YFP was tagged to NR2A or ATD-deleted NR2A subunit (left two columns). The right column was from surface staining using anti-GFP antibody and Cy3-conjugated secondary antibody. Scale bar, 10 μm. B, the percentages of cells with detectable surface labeling were determined for >200 YFP-expressing cells for each combination of cDNAs in three experiments. The gray boxes represent YFP. The bar graphs represent mean ± S.E. **, p < 0.001, ANOVA. C, Surface (black) and total YFP (white) expression. More than 60 YFP-expressing cells for each combination of cDNAs were analyzed in three experiments. **, p < 0.001, ANOVA. D, representative glutamate-evoked currents recorded from HEK 293 cells. Glutamate (100 μm) and glycine (10 μm) were added to evoke currents. E, summary data showing the average peak amplitude of the whole-cell currents when co-expressing NR1a or ATD-deleted NR1a and NR2A or ATD-deleted NR2A subunits. The numbers above the histogram bars indicate the number of cells responding of the total number of recorded cells.

The Heteromers between the ATD-deleted NR1a and the Full-length NR2A Were Formed but Retained in the ER

We further compared the surface expression of full-length NR1a or ATD-deleted NR1a subunits co-expressed with GFP-tagged NR2A or NR2B subunits in HEK 293 cells using FACS analysis. We found that co-expression of NR1a/GFP-NR2A or NR1a/GFP-NR2B led to robust surface expression, with the percentage of GFP-positive cells showing surface expression being 68.0 or 71.7% (supplemental Fig. 2A), respectively. In addition, when ATD-deleted NR1a and GFP-NR2B were co-expressed, the percentage was decreased but still relatively high (50.3%). However, the percentage of GFP-positive cells showing surface expression of NR1aΔATD/GFP-NR2A was quite low (4.1%) and was similar to that of the HEK 293 cells expressing GFP-NR2A alone (3.8%) (supplemental Fig. 2A). Taken together, results from FACS measurements were quantitatively consistent with the previous immunostaining and functional data, revealing that NR1aΔATD/NR2B were able to express in the surface membrane but not NR1aΔATD/NR2A.

One possible reason for NR1aΔATD/GFP-NR2A unable to express in the cell membrane was that ATD-deleted NR1a subunits were not able to co-assemble with NR2A subunits. In previous studies, we analyzed the assembly of native NMDA receptor subunits using a three-cube FRET measurement (14). With the same approach, we found that FRET signals were produced when CFP-NR1aΔATD and YFP-NR1aΔATD or CFP-NR1aΔATD and YFP-NR2A were co-transfected into HEK 293 cells, with FRET ratios (FR) of 1.43 ± 0.04 (n = 35) or 1.47 ± 0.09 (n = 30), respectively (Fig. 3A). These values were significantly different from the FR value (1.01 ± 0.02, n = 32; p < 0.01) obtained from the co-expression of CFP-NR1a and GABAA α1-YFP (14). In addition, when CFP-NR1aΔATD and GABAA α1-YFP were co-transfected, the FR value was 1.09 ± 0.09 (n = 38) and showed no significant difference from that obtained from the co-expression of CFP-NR1a and GABAA α1-YFP (14). The results confirmed that the deletion of ATD did not affect the assembly of NR1a and NR2A subunits.

FIGURE 3.

FIGURE 3.

NR1aΔATD and full-length NR2A subunits are assembled but mainly retained in the ER. A, ATD-deleted NR1a subunits form homomers or heteromers with full-length NR2A subunits analyzed by three-cube FRET measurement. Black boxes indicate CFP, and gray boxes indicate YFP. FR is expected to be 1 when there is no FRET and above 1 when FRET does occur. **, p < 0.01 versus CFP-NR1aΔATD/α1-YFP, unpaired t test. B, glycosylation properties of glutamate receptor subunits. GFP-NR2A, when co-expressed with the wild-type NR1a subunit, showed detectable sensitivity but was not completely sensitive to Endo H, indicating that under such conditions, GFP-NR2A entered Golgi. In contrast, when co-expressed with NR1aΔATD, GFP-NR2A was completely sensitive to Endo H, indicating that under such conditions, GFP-NR2A was retained in the ER. C, immunocytochemical analysis revealed that when GFP-NR2A was co-expressed with NR1aΔATD, it mainly colocalized with NR1aΔATD and the ER marker (PDI) but not with the Golgi (58K) (insets show the boxed regions in greater detail). D, when GFP-NR2A was co-expressed with NR1a, it mainly colocalized with NR1a but not with the ER marker (PDI). The colocalization of the NR2A subunits and the Golgi (58K) was also clearly observed (insets show the boxed regions in greater detail). Scale bars, 20 μm (10 μm for the insets).

Another potential reason for NR1aΔATD/GFP-NR2A unable to express in the cell membrane was that the ATD-deleted NR1a subunits were assembled with NR2A subunits, but they were retained in the ER. To test this possibility, we examined the subcellular localization of the NR1aΔATD/NR2A receptors using confocal microscopy (Fig. 3, C and D). After NR1aΔATD and GFP-NR2A were co-transfected into COS-7 cells, NR2A colocalized extensively with NR1a and the ER marker (PDI) but not with the Golgi marker (58K) (Fig. 3C). In contrast, when GFP-NR2A was co-expressed with NR1a in COS-7 cells, NR2A colocalized with the Golgi marker (58K) (Fig. 3D). We further tested the colocalization of GFP-NR2A when co-expressed with NR1aΔATD with the proteosome, endosome, and lysosome markers. The data showed that NR2A under such conditions was not colocalized with these markers (supplemental Fig. 3). To confirm the ER retention of NR1aΔATD/NR2A, we examined its glycosylation state. Immunoblots with GFP antibody showed that GFP-NR2A, when co-expressed with the wild-type NR1a subunit, was not completely sensitive to Endo H, indicating that under such conditions, GFP-NR2A entered Golgi (Fig. 3B). In contrast, when co-expressed with the ATD-deleted NR1a subunit, GFP-NR2A was completely sensitive to Endo H, indicating that under such conditions, GFP-NR2A was retained in the ER (Fig. 3B). Taken together, these biochemical and immunocytochemical results provide strong evidence that, when co-expressed with NR1aΔATD, the NR2A subunits were almost exclusively retained in the ER and failed to reach the Golgi or other degradation apparatus.

NR2A ATD but Not NR2B ATD Possesses an ER Retention Signal

The results described above suggest that the NR2A ATD may play a role in controlling the trafficking of NMDA receptors that is different from the NR2B ATD. To further test this possibility, we exchanged the ATDs between NR2A and NR2B and tested whether these chimeras could form functional channels in the cell membrane (Fig. 4A) with wild type or ATD-deleted NR1a subunits. The results showed that when the YFP-NR1a subunit was co-transfected with NR2AATD-2B or NR2BATD-2A, significant positive surface labeling was detected: 63.0 ± 4.3 and 64.3 ± 2.3%, respectively (Fig. 4, B and C). However, when YFP-NR1aΔATD was co-expressed with NR2BATD-2A, no surface expression was observed: 0.7 ± 0.7% (Fig. 4, B and C). In contrast, when YFP-NR1aΔATD was co-expressed with NR2AATD-2B, positive surface labeling was again detected: 39.3 ± 6.4% (Fig. 4, B and C). Furthermore, glutamate-evoked currents were recorded from YFP-NR1a/NR2BATD-2A, YFP-NR1a/NR2AATD-2B, or YFP-NR1aΔATD/NR2AATD-2B co-transfected cells; the mean current amplitudes in picoamperes were 107.63 ± 21.50 (n = 4), 113.50 ± 33.61 (n = 4), and 148.45 ± 59.25 (n = 4), respectively (Fig. 4D). These results again indicated that it is the NR2A ATD that caused the NR1aΔATD/NR2A receptors to fail to express on the cell surface.

To further test the role of the ATD of NR subunits in membrane trafficking, we constructed a series of chimeras in which the ATD of the NR subunit was fused to the transmembrane domain of an unrelated membrane protein: pDisplay-GFP (Fig. 5A). The pDisplay vector contained an NH2-terminal murine Igκ-chain leader sequence, which directs the biosensor protein to the secretory pathway, and a COOH-terminal transmembrane domain of platelet-derived growth factor receptor, which targets the biosensor protein to the plasma membrane. This plasmid has been used in the study of the role of the GluR2 ATD in spine growth (18). As expected, the expression of GFP-ATD1a or GFP-ATD2B in HEK 293 cells resulted in robust surface labeling in nearly all GFP-expressing cells (Fig. 5, B and C). However, the majority of HEK 293 cells expressing GFP-ATD2A alone were not surface-labeled (Fig. 5B), and the positive surface labeling was 2.6 ± 0.5% (Fig. 5C). We further measured the surface expression of these chimeras of pDisplay-GFP and ATD from different NR subunits using fluorescence-activated cell sorting analysis (supplemental Fig. 2B) and found that expression of GFP-ATD1a or GFP-ATD2B led to robust surface expression with the percentage of GFP-positive cells showing surface expression being 83.1 or 81.8%, respectively. However, the percentage of GFP-positive cells containing surface expression of GFP-ATD2A was quite low (3.3%). Quantitative fluorescence measurements showed a dramatic difference in the intensity of surface labeling between GFP-ATD2A, GFP-ATD1a, or GFP-ATD2B; the intensities of total GFP fluorescence were not significantly different among these GFP-tagged ATD-pDisplay chimeras (Fig. 5D). More interestingly, when co-expressing ATD1a and GFP-ATD2A, most cells showed detectable surface staining, with 70.8 ± 3.1% positive surface labeling (Fig. 5, B and C). However, no positive surface staining was detected when co-expressing ATDGluR2 and GFP-ATD2A (3.03 ± 1.6%) (supplemental Fig. 4), which further indicated that the ER retention signal of NR2A ATD was specifically masked by NR1a ATD. In addition, when the GFP-ATD1a, GFP-ATD2B, or GFP-ATD2A was expressed in hippocampal neurons, similar results were obtained. Clear surface staining was detected when neurons expressed GFP-ATD1a or GFP-ATD2B, whereas virtually no surface staining was observed when they expressed GFP-ATD2A (Fig. 6, A–C).

FIGURE 6.

FIGURE 6.

NR2A ATD was not trafficked to the surface membrane in hippocampal neurons, and its A2 segment was responsible for ER retention. Hippocampal neurons transfected with the indicated cDNAs at 5 days in vitro were surface-stained with anti-GFP antibody at 7 days in vitro (A and D). Scale bar, 20 μm. The percentages of neurons with detectable surface labeling were determined for >50 GFP-expressing neurons for each combination of cDNAs in three experiments (B and E). Gray boxes, GFP; bar graphs, mean ± S.E. Intensity per unit area represents mean ± S.E. of the fluorescence intensity per unit area obtained for surface expression (black) or total GFP expression (white), and more than 30 GFP-expressing neurons for each combination of cDNAs in three experiments were analyzed (C and F). **, p < 0.01, ANOVA.

We next compared the intracellular distribution of GFP-ATD2A with GFP-ATD2B in COS-7 cells. The immunostaining results showed that GFP-ATD2A exclusively co-localized with the ER marker (PDI) but not with the Golgi marker (58K) (Fig. 7). In contrast, the GFP-ATD2B co-localized with both markers (Fig. 7). Together with previous data, our results indicate that the NR2A ATD but not the NR2B ATD contains an ER retention signal. In addition, the assembly of NR2A ATD with NR1a ATD is able to negate this ER retention signal.

FIGURE 7.

FIGURE 7.

NR2A ATD is retained in the ER while NR2B ATD is delivered to the Golgi. GFP-ATD2A or GFP-ATD2B was transfected into COS-7 cells. Cells were immunostained with PDI as a marker for ER or 58K as a marker for Golgi and were imaged using confocal laser-scanning microscopy (Olympus). ATD2A colocalized with the ER marker but not with the Golgi marker, whereas ATD2B colocalized with both the ER and Golgi markers (insets show the boxed regions in greater detail). Scale bars, 20 μm (10 μm for the insets).

The ER Retention Signal Is Located in the A2 Segment of the NR2A ATD

To further clarify the location of this ER retention signal in the NR2A ATD, we divided NR2A ATD into four segments, termed A1–A4, according to homology with the leucine-, isoleucine-, and valine-binding proteins and the ATD of metabotropic glutamate receptors (4) (Fig. 8A). A1 and A3 correspond to the regions forming lobe-1, and A2 and A4 correspond to those forming lobe-2. A1, A2, and A3 combined comprise about 90% of the ATD sequence, whereas A4 is relatively short and may function as a linker between ATD and S1. We therefore focused our attention on the A1–A3 segments. We inserted the A1, A2, or A3 segment of the NR2A subunit into NR2AΔATD (Fig. 8A) and named the products NR2AΔATD-A1, NR2AΔATD-A2, or NR2AΔATD-A3, respectively. We co-expressed these chimeras with the YFP-tagged NR1a subunit or with the YFP-tagged, ATD-deleted NR1a subunit. We found that when NR2AΔATD-A1 was co-expressed with YFP-NR1a or YFP-NR1aΔATD, significant positive surface labeling was detected in 51.0 ± 3.5 and 48.3 ± 6.1% of the YFP-positive cells, respectively. When NR2AΔATD-A3 was co-expressed with YFP-NR1a or YFP-NR1aΔATD, significant positive surface labeling was also detected in 42.3 ± 1.1 and 46.0 ± 7.9%, respectively. However, when NR2AΔATD-A2 was co-expressed with YFP-NR1aΔATD, the percentage of positive surface labeling was significantly reduced to only 7.4 ± 0.3%, indicating that the surface expression of the YFP-NR1aΔATD/NR2AΔATD-A2 complex was almost completely abolished. When NR2AΔATD-A2 was co-expressed with YFP-NR1a, the percentage significantly increased to 23.3 ± 1.6% (Fig. 8B). We further inserted the A2 segment of the NR2B subunit (Fig. 8A) into NR2AΔATD, named NR2AΔATD-A2-2B, and co-expressed this chimera with the YFP-tagged NR1a subunit or with the ATD-deleted NR1a subunit. We found that the percentages of positive surface labeling were 57.7 ± 7.8 and 58.7 ± 5.9%, respectively (Fig. 8B), which indicated that the A2 segment of NR2B has no ER retention function. More interestingly, when we substituted the A2 segment of NR2B with that of the NR2A subunit (named NR2BA2-2A) and co-expressed it with YFP-NR1a, the percentage of positive surface expression was 51.6 ± 8.0%, whereas when YFP-NR1aΔATD/NR2BA2-2A were co-expressed, the percentage was 2.3 ± 0.2%. These results indicate that the A2 segment of the NR2A subunit, but not that of the NR2B subunit, acts as a dominant ER retention signal in the NR1a/NR2A complex.

We further tested the ER retention signal using chimeras of different segments of the NR2A or NR2B ATD and pDisplay (Fig. 8C). When the A2 segment of NR2B ATD was fused into the pDisplay-GFP and transfected into HEK 293 cells, significant surface staining was observed (76.9 ± 6.0%) (Fig. 8D). However, almost no surface staining was seen when the A2 segment of NR2A ATD was fused into the pDisplay-GFP, with the percentage of positive surface labeling being 1.0 ± 1.0%. We further constructed a chimera in which the A2 segment of the NR2B ATD was substituted with the A2 segment of the NR2A ATD (named GFP-ATD2B-A2-2A) (Fig. 8C). When GFP-ATD2B-A2-2A was expressed alone in HEK 293 cells, it was almost all retained in the ER, with the positive surface labeling being 5.5 ± 2.2% (Fig. 8D). However, when co-expressed with ATD1a, GFP-ATD2B-A2-2A was transported to the cell surface, with the positive surface labeling being 67.5 ± 3.3% (Fig. 8D). In addition, when these constructs were expressed in hippocampal neurons, similar results were obtained (Fig. 6, D–F). When GFP-A22A or GFP-ATD2B-A2-2A was expressed in hippocampal neurons, no surface staining was detected. However, when GFP-A22B or ATD1a/GFP-ATD2B-A2-2A was expressed in hippocampal neurons, clear surface staining was detected. This result was in close agreement with the previous results and confirmed that the A2 segment of the NR2A subunit but not the A2 segment of the NR2B subunit contained an ER retention signal.

The A2 segment of NR2A or NR2B has ∼130 amino acid residues. To further screen for any possible retention motif in this segment, we generated a series of point mutations in GFP-ATD2A (Fig. 8E). Ten amino acids that are different between the NR2A A2 segment and the NR2B A2 segment according to sequence alignment were chosen for mutagenesis (Fig. 8E). Mutants were screened by surface staining using anti-GFP antibody in HEK 293 cells. Unfortunately, no mutation resulted in a significant increase in the surface labeling of GFP-ATD2A. The percentages of surface labeling for I176Y, F186K, M200L, A213S, S225P, D234E, L238Y, E242V, F253Y, and K270S were 1.7 ± 1.7, 1.7 ± 1.7, 0.8 ± 0.4, 0.5 ± 0.5, 1.3 ± 1.3, 0.7 ± 0.6, 1.9 ± 1.1, 3.2 ± 0.6, 1.3 ± 1.3, and 2.8 ± 1.6%, respectively. These results suggest that either these residues are not involved in the ER retention of NR2A ATD or each of them alone is not sufficient for this retention.

In order to locate the ER retention signal, we split the A2 segment into three parts, named A22A-a (Ile151–Asp192), A22A-b (Asn193–Leu238), and A22A-c (Ile239–Asp282), and fused these parts individually into pDisplay-GFP (Fig. 8F). Unexpectedly, surface staining showed that all three of these chimeras were expressed on the surface membrane, and the percentages of surface labeling were 79.5 ± 1.5% for A22A-a, 75.6 ± 4.9% for A22A-b, and 77.3 ± 1.6% for A22A-c (Fig. 8G). Fluorescence intensity analysis of surface labeling or total GFP expression showed no significant difference among these three chimeras (Fig. 8H). Together with the point mutation results, these findings suggest that it is likely that the overall structure or conformation of the A2 segment, instead of an isolated sequence, may be involved in the ER retention of the NR2A ATD.

DISCUSSION

NMDA receptors play important roles in both normal brain function and neurological and psychiatric disorders. The number and composition of heteromeric NMDA receptors on the cell surface determine its activity in response to particular stimuli. Therefore, understanding the assembly and trafficking of the NMDA receptor is pivotal for understanding the mechanisms of its diverse functions. In this study, we found that the NR2A ATD contains an ER retention signal, and the NR1a ATD is necessary for overcoming this retention signal. In contrast, the NR2B ATD has no such retention signal. Our findings indicate that NR2A-containing NMDA receptors have an ER quality control mechanism different from that of NR2B-containing NMDA receptors.

NR2A ATD Contains an ER Retention Signal

ER retention is a common feature of the quality control mechanism for complex proteins, ensuring that unassembled or otherwise defective proteins are not released from the ER (19, 20). The NMDA receptor is a heteromeric complex. Most NR1 splice variants and NR2 subunits are retained in the ER when expressed alone. When expressed together, they assemble efficiently and form functional receptors in the cell membrane. This indicates that more restrictive mechanisms are required for the ER quality control of NMDA receptors. In the present study, we found that the ATD of the NR2A subunit contains an ER retention signal (Fig. 2). We narrowed down this ER retention signal to the A2 segment of the NR2A ATD, which contains about 100 amino acids (Fig. 8). ER retention effects were abolished when the A2 segment was further divided into three parts. In addition, mutagenesis of selected amino acids in the A2 segment of NR2A ATD failed to revert the ER retention. Together, these findings suggest that the A2 segment contains a multiple site-dependent or a conformation-dependent ER retention motif. It is unlikely that a specific motif within the A2 segment is responsible for retention. ATD of the NMDA receptor is facing the extracellular or ER luminal side. There are precedents of ER retention associated with extracellular domains. For example, the extracellular domains of T cell antigen receptor α or β chains are involved in ER retention (21, 22). Kv1α subunits also contain a dominant ER retention signal in their extracellular pore region (23); an ER protein with a domain structurally resembling that of snake dendrotoxins may be involved in ER retention.

Previous studies have shown that the NR1a subunit contains two ER retention motifs, RRR and KKK, in its C1 cassette (24, 25) and potential ER retention signals in its TM3, and the NR2B subunit possesses ER retention signals in its TM3 as well as its COOH terminus (10, 12, 26). The COOH terminus of the NR2A subunit also has been shown to play a role in ER retention (10). We found that indeed the ATD-deleted NR2A subunits, when expressed alone in heterogeneous cells, were retained in the ER (data not shown), indicating an ER retention signal located in the other part of the NR2A subunit. Taken together, these studies are consistent with the idea that multiple ER retention signals are present in the NR subunits.

The ER Retention Signal in NR2A ATD Is Masked by NR1a ATD

Recently, increasing evidence indicates that the ATD is not essential for assembly or gating of NMDA receptors but rather plays a modulatory role (2731). Here, using truncated NR subunits combined with FRET measurements, we found that deletion of the ATD did not eliminate the homo- or hetero-oligomerization of NR subunits in living HEK 293 cells (Fig. 3A). These results further indicate that the ATD is not a crucial element for subunit assembly. In addition, our results suggested a novel mechanism for the modulatory role of ATD. We showed that the ER retention signal in NR2A ATD was masked by the NR1a ATD but not the GluR2 ATD (Fig. 5 and supplemental Fig. 4), suggesting that the NR1a ATD can interact specifically with the NR2A ATD and negate the ER retention signals in the NR2A ATD.

The mechanism underlying the masking of the NR2A ATD by the NR1a ATD is still unclear. Also, the specific region of NR1a ATD involved in this process remains to be identified. The ER retention mechanism observed in Kv1α channels (23) suggests that it is possible that certain ER protein may bind to the NR2A ATD, in particular the A2 segment, and lead to its retention in the ER. The assembly of the NR1a ATD with the NR2A ATD may cause conformational changes of the NR2A ATD that result in its release from ER retention. It is also possible that the assembly of the NR1a ATD with the NR2A ATD may increase the overall structural stability of the NR2A subunit (32). A recent study (31) using a shorter NR1a deletion (350 amino acids instead of 390 amino acids in our study and 380 amino acids in the studies of Meddows and co-workers (17)) revealed different results that the ATD-deleted NR1a subunit can assemble with the NR2A subunit into functional receptors in Xenopus oocytes. We attribute this discrepancy to the different lengths of deletion our two groups used. In addition, these results suggest that the region of the NR1a ATD after 350 amino acids is important in masking the ER retention signal of the NR2A ATD.

NR2A ATD Contains an ER Retention Signal; NR2B ATD Does Not

NMDA receptors containing different NR2 subunits exhibit different channel properties, such as current kinetics and conductance (3335). However, the structure-function relationships of NMDA receptors are still uncertain. In the present study, we identified an ER retention signal that occurs in the NR2A ATD but not in the NR2B ATD. The finding provides evidence that the ER quality control mechanism of NR2A subunits is different from that of NR2B subunits. How this difference affects the functional heterogeneity of NMDA receptor subtypes remains to be determined. Nonetheless, these results suggest that the NR2A subunit may have more restrictive “structural checkpoints” than the NR2B subunit does in the ER quality control pathway. One potential consequence of this difference is to ensure the proper folding of NR2A subunits and proper assembly of the NR1a/NR2A receptor subtype. Alternatively, it is possible that the difference provides a potential mechanism to regulate the ratio of the expression of NR2A-containing NMDA receptors and NR2B-containing NMDA receptors through modulation of the preference of assembly of different NR2 subunits with NR1 subunits. Recently, several studies have indicated that under special conditions, such as inflammatory or degenerative diseases of the central nervous system, matrix metalloproteinases cleave the NR1a subunit at the extracellular NH2-terminal domain and modify NMDA receptor function (36, 37). Tissue-type plasminogen activator is also known to bind to and then cleave the ATD of the NR1 subunit at arginine 260, which serves as a necessary step to enhance NMDA receptor signaling in neurons (38, 39). Based on these observations, it is possible that a similar mechanism may also exist in the ER lumen, where various extracellular and intracellular stimuli can regulate the interaction of the NR1a ATD with the NR2A ATD and control the trafficking of the NR1a/NR2A receptor subtype.

Supplementary Material

Supplemental Data

Acknowledgment

We thank Prof. Iain C. Bruce for critical reading of the manuscript.

*

This work was supported by National Natural Science Foundation of China Grants 30730038 and 30800308 and National Basic Research Program of China Grant G2002CB713808 (to J. H. L.). This work was also supported by the National Institutes of Health Grant REY016754A and American Heart Association Grant 0665201Y (to J. Z.).

Inline graphic

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1–4.

2
The abbreviations used are:
iGluR
ionotropic glutamate receptor
AMPA
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
ATD
amino-terminal domain
FRET
fluorescence resonance energy transfer
GABAA
γ-aminobutyric acid type A
NMDA
N-methyl-d-aspartate
NR
NMDA receptor
PBS
phosphate-buffered saline
ER
endoplasmic reticulum
CFP
cyan fluorescent protein
YFP
yellow fluorescent protein
GFP
green fluorescent protein
ANOVA
analysis of variance
PDI
protein-disulfide isomerase.

REFERENCES

  • 1.Dingledine R., Borges K., Bowie D., Traynelis S. F. (1999) Pharmacol. Rev. 51, 7–61 [PubMed] [Google Scholar]
  • 2.Hollmann M., Maron C., Heinemann S. (1994) Neuron 13, 1331–1343 [DOI] [PubMed] [Google Scholar]
  • 3.Madden D. R. (2002) Nat. Rev. 3, 91–101 [DOI] [PubMed] [Google Scholar]
  • 4.O'Hara P. J., Sheppard P. O., Thøgersen H., Venezia D., Haldeman B. A., McGrane V., Houamed K. M., Thomsen C., Gilbert T. L., Mulvihill E. R. (1993) Neuron 11, 41–52 [DOI] [PubMed] [Google Scholar]
  • 5.Hsiao C. D., Sun Y. J., Rose J., Wang B. C. (1996) J. Mol. Biol. 262, 225–242 [DOI] [PubMed] [Google Scholar]
  • 6.Armstrong N., Sun Y., Chen G. Q., Gouaux E. (1998) Nature 395, 913–917 [DOI] [PubMed] [Google Scholar]
  • 7.McIlhinney R. A., Le Bourdellès B., Molnár E., Tricaud N., Streit P., Whiting P. J. (1998) Neuropharmacology 37, 1355–1367 [DOI] [PubMed] [Google Scholar]
  • 8.Okabe S., Miwa A., Okado H. (1999) J. Neurosci. 19, 7781–7792 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fukaya M., Kato A., Lovett C., Tonegawa S., Watanabe M. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 4855–4860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hawkins L. M., Prybylowski K., Chang K., Moussan C., Stephenson F. A., Wenthold R. J. (2004) J. Biol. Chem. 279, 28903–28910 [DOI] [PubMed] [Google Scholar]
  • 11.Yang W., Zheng C., Song Q., Yang X., Qiu S., Liu C., Chen Z., Duan S., Luo J. (2007) J. Biol. Chem. 282, 9269–9278 [DOI] [PubMed] [Google Scholar]
  • 12.Horak M., Chang K., Wenthold R. J. (2008) J. Neurosci. 28, 3500–3509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Luo J. H., Fu Z. Y., Losi G., Kim B. G., Prybylowski K., Vissel B., Vicini S. (2002) Neuropharmacology 42, 306–318 [DOI] [PubMed] [Google Scholar]
  • 14.Qiu S., Hua Y. L., Yang F., Chen Y. Z., Luo J. H. (2005) J. Biol. Chem. 280, 24923–24930 [DOI] [PubMed] [Google Scholar]
  • 15.Erickson M. G., Alseikhan B. A., Peterson B. Z., Yue D. T. (2001) Neuron 31, 973–985 [DOI] [PubMed] [Google Scholar]
  • 16.Erickson M. G., Liang H., Mori M. X., Yue D. T. (2003) Neuron 39, 97–107 [DOI] [PubMed] [Google Scholar]
  • 17.Meddows E., Le Bourdelles B., Grimwood S., Wafford K., Sandhu S., Whiting P., McIlhinney R. A. (2001) J. Biol. Chem. 276, 18795–18803 [DOI] [PubMed] [Google Scholar]
  • 18.Saglietti L., Dequidt C., Kamieniarz K., Rousset M. C., Valnegri P., Thoumine O., Beretta F., Fagni L., Choquet D., Sala C., Sheng M., Passafaro M. (2007) Neuron 54, 461–477 [DOI] [PubMed] [Google Scholar]
  • 19.Ellgaard L., Helenius A. (2003) Nat. Rev. Mol. Cell Biol. 4, 181–191 [DOI] [PubMed] [Google Scholar]
  • 20.Fleck M. W. (2006) Neuroscientist 12, 232–244 [DOI] [PubMed] [Google Scholar]
  • 21.Shin J., Lee S., Strominger J. L. (1993) Science 259, 1901–1904 [DOI] [PubMed] [Google Scholar]
  • 22.Lee S. J. (1998) Exp. Mol. Med. 30, 159–164 [DOI] [PubMed] [Google Scholar]
  • 23.Vacher H., Mohapatra D. P., Misonou H., Trimmer J. S. (2007) FASEB J. 21, 906–914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Standley S., Roche K. W., McCallum J., Sans N., Wenthold R. J. (2000) Neuron 28, 887–898 [DOI] [PubMed] [Google Scholar]
  • 25.Horak M., Wenthold R. J. (2009) J. Biol. Chem. 284, 9683–9691 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Stephenson F. A., Cousins S. L., Kenny A. V. (2008) Mol. Membr. Biol. 25, 311–320 [DOI] [PubMed] [Google Scholar]
  • 27.Chen G. Q., Cui C., Mayer M. L., Gouaux E. (1999) Nature 402, 817–821 [DOI] [PubMed] [Google Scholar]
  • 28.Fayyazuddin A., Villarroel A., Le Goff A., Lerma J., Neyton J. (2000) Neuron 25, 683–694 [DOI] [PubMed] [Google Scholar]
  • 29.Zheng F., Erreger K., Low C. M., Banke T., Lee C. J., Conn P. J., Traynelis S. F. (2001) Nat. Neurosci. 4, 894–901 [DOI] [PubMed] [Google Scholar]
  • 30.Paoletti P., Perin-Dureau F., Fayyazuddin A., Le Goff A., Callebaut I., Neyton J. (2000) Neuron 28, 911–925 [DOI] [PubMed] [Google Scholar]
  • 31.Madry C., Mesic I., Betz H., Laube B. (2007) Mol. Pharmacol. 72, 1535–1544 [DOI] [PubMed] [Google Scholar]
  • 32.Atlason P. T., Garside M. L., Meddows E., Whiting P., McIlhinney R. A. (2007) J. Biol. Chem. 282, 25299–307 [DOI] [PubMed] [Google Scholar]
  • 33.Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P. H. (1992) Science 256, 1217–1221 [DOI] [PubMed] [Google Scholar]
  • 34.Lynch D. R., Lawrence J. J., Lenz S., Anegawa N. J., Dichter M., Pritchett D. B. (1995) J. Neurochem. 64, 1462–1468 [DOI] [PubMed] [Google Scholar]
  • 35.Flint A. C., Maisch U. S., Weishaupt J. H., Kriegstein A. R., Monyer H. (1997) J. Neurosci. 17, 2469–2476 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Szklarczyk A., Ewaleifoh O., Beique J. C., Wang Y., Knorr D., Haughey N., Malpica T., Mattson M. P., Huganir R., Conant K. (2008) FASEB J. 22, 3757–3767 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Pauly T., Ratliff M., Pietrowski E., Neugebauer R., Schlicksupp A., Kirsch J., Kuhse J. (2008) PLOS One 3, e2681–e2691 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E. T., Vivien D., Buisson A. (2001) Nat. Med. 7, 59–64 [DOI] [PubMed] [Google Scholar]
  • 39.Fernández-Monreal M., López-Atalaya J. P., Benchenane K., Cacquevel M., Dulin F., Le Caer J. P., Rossier J., Jarrige A. C., Mackenzie E. T., Colloc'h N., Ali C., Vivien D. (2004) J. Biol. Chem. 279, 50850–50856 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Data

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES